Geneos Wealth Management Inc. Sells 10,330 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Geneos Wealth Management Inc. reduced its stake in Gilead Sciences, Inc. by 17.9%, selling 10,330 shares and maintaining a total of 47,434 shares valued at approximately $5.3 million.
• Analysts have upgraded Gilead's stock ratings, with Truist Financial raising its target price from $108.00 to $127.00 and noting a consensus rating of "Moderate Buy" with an average target price of $115.39.
• Gilead announced a quarterly dividend of $0.79 per share, amounting to an annualized dividend of $3.16 and a dividend yield of 2.7%, payable on September 29th.

Geneos Wealth Management Inc. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 47,434 shares of the biopharmaceutical company's stock after selling 10,330 shares during the period. Geneos Wealth Management Inc.'s holdings in Gilead Sciences were worth $5,315,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the 1st quarter valued at about $25,000. Activest Wealth Management lifted its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the 1st quarter valued at about $29,000. Colonial Trust Advisors lifted its holdings in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its holdings in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the transaction, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,000 shares of company stock worth $9,371,330. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on GILD. UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Stock Performance

Shares of GILD traded down $3.31 during trading hours on Friday, hitting $114.55. The company had a trading volume of 6,466,956 shares, compared to its average volume of 5,830,447. The firm has a market cap of $142.13 billion, a price-to-earnings ratio of 22.82, a PEG ratio of 0.80 and a beta of 0.36. The business has a fifty day moving average of $114.04 and a 200-day moving average of $110.09. Gilead Sciences, Inc. has a 12 month low of $81.57 and a 12 month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.